Waltham, MA-based Syndax Pharmaceuticals named former AstraZeneca chief medical officer Briggs Morrison its new CEO, and Michael Metzger, onetime Regado Biosciences president and CEO, its new president. Morrison and and Metzger are replacing former leader Arlene Morris—whose name was conspicuously absent from the news release. FierceBiotech first reported news of Morrison’s departure from AstraZeneca last week. Read more here for the immuno-oncology focused strategy that Syndax—which flirted with an IPO last year under Morris—intends to pursue.
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
From Our Editors · Special Report
Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemic
